Drug-resistant epilepsy drug Ontozry backed by NICE
pharmaphorum
NOVEMBER 16, 2021
The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least two prior antiseizure medicines.
Let's personalize your content